Renasant Bio

Renasant Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.

Company Details

Employees
24
Address
Berkeley, California, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Berkeley, California
Looking for a particular Renasant Bio employee's phone or email?

Renasant Bio Questions

News

Renasant Bio Launches to Pioneer Next-Generation Disease-Modifying Small Molecule Treatments for ADPKD - Business Wire

Renasant Bio Launches to Pioneer Next-Generation Disease-Modifying Small Molecule Treatments for ADPKD Business Wire

Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding - BioPharma Dive

Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding BioPharma Dive

Cyst-ine Chapel: Renasant Bio Launches to Solve Complex Kidney Disease ADPKD - Inside Precision Medicine

Cyst-ine Chapel: Renasant Bio Launches to Solve Complex Kidney Disease ADPKD Inside Precision Medicine

Renasant Bio launches to develop kidney disease treatment - Chemical & Engineering News

Renasant Bio launches to develop kidney disease treatment Chemical & Engineering News

Renasant Bio Raises $54.5M in Seed Funding - FinSMEs

Renasant Bio Raises $54.5M in Seed Funding FinSMEs

Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million - statnews.com

Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million statnews.com

Renasant Bio debuts with sights on root causes of polycystic kidney disease - FirstWord Pharma

Renasant Bio debuts with sights on root causes of polycystic kidney disease FirstWord Pharma

East Bay startup led by former 23andMe exec snags $54.5 million to target deadly kidney disease - The Business Journals

East Bay startup led by former 23andMe exec snags $54.5 million to target deadly kidney disease The Business Journals

Renasant Bio Launches With $54.5 Million Seed Funding To Develop Kidney Disease Treatments - Pulse 2.0

Renasant Bio Launches With $54.5 Million Seed Funding To Develop Kidney Disease Treatments Pulse 2.0

Top Renasant Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant